These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 721835)
21. [Basic characteristics of a live influenza vaccine for children from type A influenza (H1N1 and H3N2) used separately and in combination]. Rudenko LG; Shvartsman IaS; Ispolatova AV; Grigor'eva EP; Drinevskiĭ VP Vopr Virusol; 1989; 34(1):29-34. PubMed ID: 2728404 [TBL] [Abstract][Full Text] [Related]
22. [Enhanced immunogenicity of influenza virus hemagglutinin when incorporated into liposomes]. Ishbaeva RI; Guliako AA; Simonov AN; Kleppish I; Makhov AM Vopr Virusol; 1989; 34(2):237-40. PubMed ID: 2763517 [No Abstract] [Full Text] [Related]
23. Protection against homologous influenza challenge by genetic immunization with SFV-RNA encoding Flu-HA. Dalemans W; Delers A; Delmelle C; Denamur F; Meykens R; Thiriart C; Veenstra S; Francotte M; Bruck C; Cohen J Ann N Y Acad Sci; 1995 Nov; 772():255-6. PubMed ID: 8546401 [No Abstract] [Full Text] [Related]
24. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Byars NE; Allison AC; Harmon MW; Kendal AP Vaccine; 1990 Feb; 8(1):49-56. PubMed ID: 2316284 [TBL] [Abstract][Full Text] [Related]
25. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. Oxford JS; Schild GC; Potter CW; Jennings R J Hyg (Lond); 1979 Feb; 82(1):51-61. PubMed ID: 105040 [TBL] [Abstract][Full Text] [Related]
26. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Donnelly JJ; Friedman A; Martinez D; Montgomery DL; Shiver JW; Motzel SL; Ulmer JB; Liu MA Nat Med; 1995 Jun; 1(6):583-7. PubMed ID: 7585127 [TBL] [Abstract][Full Text] [Related]
27. Immune response of adults to sequential influenza vaccination. Powers RD; Hayden FG; Samuelson J; Gwaltney JM J Med Virol; 1984; 14(2):169-75. PubMed ID: 6491643 [TBL] [Abstract][Full Text] [Related]
29. Pitfalls of single radial immunodiffusion techniques used for the quantification of influenza haemagglutinin. Johannsen R; Hinz J; Gruschkau H Dev Biol Stand; 1986; 65():255-60. PubMed ID: 3104116 [TBL] [Abstract][Full Text] [Related]
30. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Webster RG; Fynan EF; Santoro JC; Robinson H Vaccine; 1994 Dec; 12(16):1495-8. PubMed ID: 7879412 [TBL] [Abstract][Full Text] [Related]
31. Secretory antibody response to haemagglutinin of influenza virus A/swine and A/victoria in humans after administration of split and whole-virion vaccine. Hrusková J; Syrůcek L; Záradová H; Vonka V; Plesník V; Heinz F; Stárek M; Domorázková E J Biol Stand; 1978 Jul; 6(3):181-5. PubMed ID: 721837 [No Abstract] [Full Text] [Related]
32. [The antibody activity to synthetic C-terminal fragments of the heavy-chain hemagglutinins of influenza virus A subtypes H1 and H3]. Mazurkova NA; Kalashnikov VV; Mizenko GA; Samukov VV; Podcherniaeva RIa Vopr Virusol; 1990; 35(4):283-6. PubMed ID: 2256311 [TBL] [Abstract][Full Text] [Related]
33. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes. Wright PF; Bhargava M; Johnson PR; Thompson J; Karzon DT Vaccine; 1985 Sep; 3(3):305-8. PubMed ID: 3904259 [TBL] [Abstract][Full Text] [Related]
34. Morphology and antigenicity studies on reassortant influenza (H3N2) viruses for use in inactivated vaccines. Pemberton RM; Jennings R; Smith TL J Hyg (Lond); 1985 Apr; 94(2):229-39. PubMed ID: 2580887 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931 [TBL] [Abstract][Full Text] [Related]
36. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981 [TBL] [Abstract][Full Text] [Related]
37. [Influenza vaccine stimulation of antibodies to different variants of influenza A virus]. Naĭkhin AN; Ispolatova AV; Tsybul'skaia NV; Sominina AA; Denisov GM Vopr Virusol; 1985; 30(3):290-6. PubMed ID: 4049840 [TBL] [Abstract][Full Text] [Related]
38. Immune response to human influenza virus hemagglutinin expressed in Escherichia coli. Davis AR; Bos T; Ueda M; Nayak DP; Dowbenko D; Compans RW Gene; 1983 Mar; 21(3):273-84. PubMed ID: 6343189 [TBL] [Abstract][Full Text] [Related]
39. [Studies on anti-neuraminidase antibody response in serum after inoculation of influenza hemagglutinin vaccines]. Hiromatsu Y; Sato Y; Inoguchi T; Umeno H; Kurosawa Y; Ishii K; Kobayashi K; Kaji M; Shingu T; Hayashida K Kansenshogaku Zasshi; 1984 May; 58(5):367-75. PubMed ID: 6434660 [No Abstract] [Full Text] [Related]
40. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. Ennis FA; Yi-Hua Q; Schild GC J Gen Virol; 1982 Feb; 58(Pt 2):273-81. PubMed ID: 7038041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]